PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
24.17%
D&A growth of 24.17% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
100.00%
Deferred tax growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-9.33%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-80.33%
Working capital is shrinking yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-249.09%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-101.42%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-72.30%
Negative CFO growth while Biotechnology median is -7.69%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-455.28%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-427.62%
Reduced investing yoy while Biotechnology median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Issuance growth of 53916.27% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.